EMA lists paediatric priorities for off-patent drugs as new EC funding nears
This article was originally published in SRA
Executive Summary
Following a two-year drought, the European Commission's seventh framework programme (FP7) is to make fresh funding available in 2013 for companies wishing to develop paediatric forms of off-patent drugs1.